197 related articles for article (PubMed ID: 24238058)
21. Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique.
Janssen BL; van de Locht LT; Fourkour A; de Smet C; Mensink EJ; van Muijen GN; de Vries TJ
Melanoma Res; 1999 Jun; 9(3):213-22. PubMed ID: 10465576
[TBL] [Abstract][Full Text] [Related]
22. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
23. Expression of MAGE genes in human colorectal carcinoma.
Mori M; Inoue H; Mimori K; Shibuta K; Baba K; Nakashima H; Haraguchi M; Tsuji K; Ueo H; Barnard GF; Akiyoshi T
Ann Surg; 1996 Aug; 224(2):183-8. PubMed ID: 8757382
[TBL] [Abstract][Full Text] [Related]
24. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Cruz CR; Gerdemann U; Leen AM; Shafer JA; Ku S; Tzou B; Horton TM; Sheehan A; Copeland A; Younes A; Rooney CM; Heslop HE; Bollard CM
Clin Cancer Res; 2011 Nov; 17(22):7058-66. PubMed ID: 21908573
[TBL] [Abstract][Full Text] [Related]
25. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Ando T; Nishimura M; Oka Y
Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.
Bell JS; Kagey JD; Barwick BG; Dwivedi B; McCabe MT; Kowalski J; Vertino PM
Epigenetics; 2016 Apr; 11(4):273-87. PubMed ID: 27082926
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.
Maddodi N; Bhat KM; Devi S; Zhang SC; Setaluri V
J Biol Chem; 2010 Jan; 285(1):242-54. PubMed ID: 19880519
[TBL] [Abstract][Full Text] [Related]
31. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.
Kondo T; Zhu X; Asa SL; Ezzat S
Clin Cancer Res; 2007 Aug; 13(16):4713-20. PubMed ID: 17699848
[TBL] [Abstract][Full Text] [Related]
32. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
33. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.
Sigalotti L; Coral S; Nardi G; Spessotto A; Cortini E; Cattarossi I; Colizzi F; Altomonte M; Maio M
J Immunother; 2002; 25(1):16-26. PubMed ID: 11924907
[TBL] [Abstract][Full Text] [Related]
34. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.
Rao M; Chinnasamy N; Hong JA; Zhang Y; Zhang M; Xi S; Liu F; Marquez VE; Morgan RA; Schrump DS
Cancer Res; 2011 Jun; 71(12):4192-204. PubMed ID: 21546573
[TBL] [Abstract][Full Text] [Related]
36. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
Hambach L; Ling KW; Pool J; Aghai Z; Blokland E; Tanke HJ; Bruijn JA; Halfwerk H; van Boven H; Wieles B; Goulmy E
Blood; 2009 Mar; 113(12):2715-22. PubMed ID: 19096014
[TBL] [Abstract][Full Text] [Related]
37. Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice.
Huang X; Kong G; Li Y; Zhu W; Xu H; Zhang X; Li J; Wang L; Zhang Z; Wu Y; Liu X; Wang X
Biomed Pharmacother; 2016 Dec; 84():447-453. PubMed ID: 27685787
[TBL] [Abstract][Full Text] [Related]
38. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
40. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
